“It's already been used in humans — and that's huge,” Dr. Sanders said. “We have treated patients for up to 20 months and they've tolerated the drug well.
Neurology Today: 3 July 2014 - Volume 14 - Issue 13 - p 22-23 doi: 10.1097/01.NT.0000452276.24201.20.
This is an extension of Robin Franklin's groups finding that RXR receptor is expressed during remyelination. They also found that getting rid of RXR-gamma prevented oligodendrocyte multiplication in culture, showing that RXR is important in remyelination.
As a next step the Sanders group plan to test this in another animal model of remyelination to test whether the findings hold up. But if successful, there is no reason why they shouldn't move ahead to a Phase II clinical trial in MS patients. It has already been found to be safe in patients with prostate cancer; so there is no need to carry out a Phase I safety study in humans (Hooray!).
PS: as it also reduces PSA levels, it may be a win win scenario for the men!